Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares

On September 1-3, 2026, MPM BioVentures 2018, L.P., a 10% owner and director of Entrada Therapeutics, sold $617,378 worth of the company's common stock, according to wire material. The sales occurred in a series of trades between September 1 and September 3, 2026, with the weighted average purchase price for each share ranging from $7.06 to $7.19.

As of the current trading day, the stock price is $7.17, marking a 30% decline year-to-date. However, it has risen 37% over the past year. InvestingPro analysis suggests the company is currently undervalued, with price targets reaching up to $25 per share. On September 1, MPM BioVentures 2018 sold 29,088 shares at an average price of $7.06 per share, with individual prices ranging from $6.80 to $7.15.

The next day, they sold an additional 25,131 shares at a weighted average price of $7.19 per share, with individual prices between $6.9601 and $7.3273. On the final day of the transactions, September 3, MPM BioVentures 2018 sold 32,263 shares at an average price of $7.17 per share, with individual prices between $7.0434 and $7.405.

These transactions left the entity indirectly owning 4,144,952 shares of Entrada Therapeutics common stock, held by various affiliated entities. Each party involved disclaims beneficial ownership, except for their respective monetary interest.